# reload+after+2024-01-22 11:48:07.951171
address1§Jinchuang Plaza
address2§Building 1, Fourth Floor 4560 Jinke Road Pudong
city§Shanghai
zip§201210
country§China
phone§86 21 6163 2588
website§https://www.zailaboratory.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
fullTimeEmployees§2036
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ying  Du Ph.D.', 'age': 57, 'title': 'Founder, Chairperson & CEO', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 1667101, 'exercisedValue': 0, 'unexercisedValue': 4758112}, {'maxAge': 1, 'name': 'Mr. Joshua L.  Smiley', 'age': 53, 'title': 'President & COO', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 647109, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rafael G.  Amado M.D.', 'age': 59, 'title': 'President and Head of Global Oncology Research & Development', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 477000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Harald  Reinhart M.D.', 'age': 71, 'title': 'President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 923330, 'exercisedValue': 68601, 'unexercisedValue': 1779}, {'maxAge': 1, 'name': 'Dr. Yajing  Chen Ph.D.', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peter  Huang Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frazor Titus  Edmondson III, J.D.', 'age': 57, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 829003, 'exercisedValue': 0, 'unexercisedValue': 4122300}, {'maxAge': 1, 'name': 'Ms. Ann E.  Beasley J.D.', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ning  Xu M.D.', 'age': 58, 'title': 'Executive VP & Head of Clinical Operations', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jonathan J.  Wang MBA, Ph.D.', 'age': 41, 'title': 'Chief Business Officer', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.186
priceToSalesTrailing12Months§10.015269
currency§USD
dateShortInterest§1702598400
forwardEps§-2.93
pegRatio§0.1
exchange§NGM
quoteType§EQUITY
shortName§Zai Lab Limited
longName§Zai Lab Limited
firstTradeDateEpochUtc§1505914200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8abb8ada-ed23-324a-aac0-9a720ac3e08a
gmtOffSetMilliseconds§-18000000
targetHighPrice§123.0
targetLowPrice§37.0
targetMeanPrice§66.46
targetMedianPrice§66.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§7.091
grossMargins§-0.29936
ebitdaMargins§-1.29488
trailingPegRatio§None
